Karen Knudsen/LinkedIn
Jul 2, 2025, 07:56
Karen Knudsen: Exactly The Kind of Science that will be Key for Continuing to Advance Immunotherapy Cancer Cures
Karen Knudsen, CEO of Parker Institute for Cancer Immunotherapy, shared a post on LinkedIn:
“Provocative new data suggest that patients with high tumor volume going into CAR T are more likely to experience serious toxicity (inc. non-relapse mortality). If we can identify high-risk patients early, we can intervene early, and keep patients safer without compromising outcomes.
This is exactly the kind of science that will be key for continuing to advance immunotherapy cancer cures and matching the right patient to the right cancer treatment, the first time. Data to build on!”
More posts featuring Karen Knudsen.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 7, 2025, 16:25
Sep 7, 2025, 15:52
Sep 7, 2025, 15:47
Sep 7, 2025, 15:37